For Healthcare Professionals

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

clipboard-pencil

About the study

The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Confirmed diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic Medullary Thyroid Cancer.
  2. Presence of measurable tumor
  3. Able to swallow medication

EXCLUSION CRITERIA

  1. Major surgery within 4 weeks before randomization
  2. Last dose of prior chemotherapy received less than 4 weeks prior to randomization
  3. Radiation therapy within the last 4 weeks prior to randomization(with exception of palliative radiotherapy)
  4. Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days
  5. Significant cardiac events
  6. Previous ZD6474 treatment
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Thyroid Cancer

Age (in years)

18 - 200

Phase

Phase 3

Participants needed

437

Est. Completion Date

Dec 2023

Treatment type

Interventional


Sponsor

Sanofi

ClinicalTrials.gov identifier

NCT00410761

Study number

D4200C00058

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.